<?xml version="1.0" encoding="UTF-8"?>
<p>Sequence comparison between the MERS-CoV nucleocapsid protein and its analog in SARS-CoV-2 revealed that there is only 48,42% of identity between them (see Figure S1), suggesting that the active ligands in MERS-CoV were unlikely to be effectively repurposed in SARS-CoV-2.</p>
